Huff Curtis W 的 Form 4 申報
Comera Life Sciences Holdings, Inc.CMRA,2024/1/3 申報
- 申報編號
- 0000950170-24-001385
- 申報時間
- 2024/1/3 20:09 ET
- 交易日
- 2023/12/29
- 申報延遲
- 5 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 2 筆衍生性交易。交易後 5 天申報。
申報人
一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Huff Curtis WCIK 0001250127 | 持股 10% 以上大股東 |
| Freebird Partners LPCIK 0001955231 | 持股 10% 以上大股東 |
| Freebird Investments LLCCIK 0001971406 | 持股 10% 以上大股東 |
非衍生性證券(表 I)
普通股等股票的取得與處分,每一列是申報上的一筆。
這份申報沒有這一類的交易。
衍生性證券(表 II)
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。
附註與備註
本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。
- F2
Pursuant to that certain Securities Purchase Agreement dated December 29, 2023, as announced in the Issuer's Current Report on Form 8-K filed with the Securities Exchange Commission on December 29, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $134,950, (i) a Senior Convertible Note in the principal amount of $134,950 (the "Note") with a one (1) year term, and (ii) a warrant to purchase up to 4,907,272 shares of Common Stock (the "Warrant" and such transactions the "Transactions").
表 II 有 1 筆交易的價格引用這則附註。
- F3
(Continued from footnote 2) The Note may be converted at any time and from time to time after December 29, 2023, at the option of the holder, at a conversion price of $0.055 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 29, 2023, and may be exercised through December 29, 2028, at an exercise price of $0.055 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company.
表 II 有 1 筆交易的價格引用這則附註。